Immunotherapies for Neurological Disorders

Unlocking the Brain's Defenses
Erscheinungsjahr 2026
ISBN: 978-0-443-44631-3
Verlag: Elsevier Science

Buch, Englisch, 350 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 449 g

Immunotherapies for Neurological Disorders: Unlocking the Brain's Defenses explores the complex intersection of both the immune and nervous systems and neurological disorders. This comprehensive guide details the vital role of immunology in understanding conditions from Alzheimer's and Parkinson's to autoimmune diseases like multiple sclerosis and Guillain-Barré syndrome. Each chapter reviews strategies, including the use of antibodies, recombinant proteins, and cutting-edge vaccine approaches to modulate immune responses in the brain. Readers will be presented with the therapeutic potential of immune cells, gene therapy, and RNA interference in combating these debilitating disorders, while also examining the role of nanotechnology in enhancing treatment efficacy.

Aimed at neurologists, immunologists, researchers, and students alike, this book serves as an essential resource for the latest advancements in neurological disease treatment.

Autoren/Hrsg.

Gautam, Akash

Morelli, Micaela

Inhaltsverzeichnis

1. Understanding the Immunological Components of Brain Disorders
2. Harnessing Antibodies for Treating Neurological Disorders
3. Strategies for Suppressing Immune Responses in the Brain
4. Modulating Brain Immunity with Recombinant Proteins
5. Peptides and Their Ligands: A New Frontier in Immunomodulation
6. Vaccines for Neurological Disorders: Preventive Strategies
7. DNA Vaccination for Neurological Disorders: A Promising Approach
8. Therapeutic Potential of Immune Cells for Neurological Disorders
9. Gene Therapy in Neurological Disorders: Modulating Immune System
10. RNA Interference in Neurological Disorders: Silencing Harmful Immune Responses
11. Nanotechnology and Immune Cells: Innovations in Therapy

Über Autor(innen)

Gautam, Akash
Dr Akash Gautam has been an Assistant Professor at the Centre for Neural and Cognitive Sciences, School of Medical Science, University of Hyderabad, India, since 2013. He also served as the guest editor for a special issue in Frontiers in Aging Neuroscience. His research interest is in Neuroscience with a specialization in the neurobiology of learning and memory, molecular mechanisms of neurodegenerative disorders, synthesis of nanoformulations and herbal therapeutics for neurological disorders. He has been conferred travel awards from national and international agencies. He has attended several workshops/training programs and presented his work in >40 conferences/seminars at both national and international levels. He has received several research grants and currently heads the molecular neurobiology laboratory at the University of Hyderabad. He has been a referee for many international journals, including Archives of physiology and biochemistry, Brain research bulletin, Frontiers in ageing neuroscience, Molecular Psychiatry, Materials Today, Neurobiology of stress and Pharmacological Reports. He has more than ten years of teaching experience in Cognitive Science, Biochemistry, Research methodology & Statistics, and Molecular neuroscience. He has also published 20 research articles in the peer-reviewed international journal, two books from Springer Nature and more than 40 book chapters. He is a member of many international scientific societies and organizations.

Morelli, Micaela
Professor Micaela Morelli is a professor of pharmacology. She joined the Center of Excellence on Neurobiology of Dependence in 2001. She became the Italian representative for the International Brain Research Organization (IBRO) in 2005 and was appointed the councilor of IBRO Western Europe Regional Committee in 2010.

She has dedicated her research interests to the study of drugs active in the central nervous system and particularly to drugs for the treatment of Parkinson’s disease.

These studies have evidenced that blockade of adenosine A2A receptors play a positive role in the symptomatic treatment of Parkinson’s disease. Behavioral studies on this topic have been correlated to specific modifications in zif-268, A2A receptors, dynorphin, enkephalin and GAD67 mRNA in the striatum. Moreover the neuroprotective and anti-inflammatory effects of A2A receptor antagonists have been evidenced in MPTP-treated pre-clinical models. These studies have resulted in clinical trials on A2A receptor antagonists in Parkinson’s patients.